NCT05215951 2025-10-15
MINOVA
AstraZeneca
Phase 2 Terminated
Clinical Trials
8 trialsNCT04862780 2025-02-10
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
Blueprint Medicines Corporation
Phase 1 Terminated
NCT05228015 2024-11-18
Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors
Ikena Oncology
Phase 1 Terminated
NCT05493501 2024-05-02
Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer
EQRx International, Inc.
Phase 3 Terminated
NCT04816214 2024-03-05
GEOMETRY-E
Novartis
Phase 3 Terminated
NCT05153408 2023-06-18
(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC
Blueprint Medicines Corporation
Phase 1 Terminated
NCT03418532 2023-03-23
MP0250 DARPin® Protein Plus Osimertinib in Patients With EGFR-mutated NSCLC
Molecular Partners AG
Phase 1 Terminated
NCT03255083 2022-01-19
DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
Daiichi Sankyo
Phase 1 Terminated